Novel p53 therapies for head and neck cancer

Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mario R. Castellanos, Quintin Pan
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2016
Materias:	Otorhinolaryngology RF1-547 Surgery RD1-811
Acceso en línea:	https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f96e30f0f9547dda9dba2c79df9c3a2
record_format	dspace
spelling	oai:doaj.org-article:7f96e30f0f9547dda9dba2c79df9c3a22021-12-02T14:21:00ZNovel p53 therapies for head and neck cancer2095-881110.1016/j.wjorl.2016.05.005https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a22016-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095881116300142https://doaj.org/toc/2095-8811Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human papillomavirus E6 protein. Inactivation of p53 is associated with poor clinical response and outcome; therefore, restoration of the p53 signaling cascade may be an effective approach to ablate HNSCC cells. Viral approaches to restore p53 activity in HNSCC have been well-studied and shown modest activity in clinical trials. Recent work has focused on high-throughput screens and rational designs to identify and develop small molecules to rescue p53 function. Several p53-targeting small molecules have demonstrated very promising activity in pre-clinical studies but have yet progressed to the clinical setting. Further development of p53 therapies, in particular chemical approaches, should be prioritized and evaluated in the HNSCC setting. Keywords: Head and neck cancer, Tumor suppressor p53, Gene therapy, Human papillomavirus, p53 mutationsMario R. CastellanosQuintin PanKeAi Communications Co., Ltd.articleOtorhinolaryngologyRF1-547SurgeryRD1-811ENWorld Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 2, Iss 2, Pp 68-75 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Otorhinolaryngology RF1-547 Surgery RD1-811
spellingShingle	Otorhinolaryngology RF1-547 Surgery RD1-811 Mario R. Castellanos Quintin Pan Novel p53 therapies for head and neck cancer
description	Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human papillomavirus E6 protein. Inactivation of p53 is associated with poor clinical response and outcome; therefore, restoration of the p53 signaling cascade may be an effective approach to ablate HNSCC cells. Viral approaches to restore p53 activity in HNSCC have been well-studied and shown modest activity in clinical trials. Recent work has focused on high-throughput screens and rational designs to identify and develop small molecules to rescue p53 function. Several p53-targeting small molecules have demonstrated very promising activity in pre-clinical studies but have yet progressed to the clinical setting. Further development of p53 therapies, in particular chemical approaches, should be prioritized and evaluated in the HNSCC setting. Keywords: Head and neck cancer, Tumor suppressor p53, Gene therapy, Human papillomavirus, p53 mutations
format	article
author	Mario R. Castellanos Quintin Pan
author_facet	Mario R. Castellanos Quintin Pan
author_sort	Mario R. Castellanos
title	Novel p53 therapies for head and neck cancer
title_short	Novel p53 therapies for head and neck cancer
title_full	Novel p53 therapies for head and neck cancer
title_fullStr	Novel p53 therapies for head and neck cancer
title_full_unstemmed	Novel p53 therapies for head and neck cancer
title_sort	novel p53 therapies for head and neck cancer
publisher	KeAi Communications Co., Ltd.
publishDate	2016
url	https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a2
work_keys_str_mv	AT mariorcastellanos novelp53therapiesforheadandneckcancer AT quintinpan novelp53therapiesforheadandneckcancer
_version_	1718391558662782976

Novel p53 therapies for head and neck cancer

Ejemplares similares